Confirming TDP2 mutation in spinocerebellar ataxia autosomal recessive 23 (SCAR23)
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received December 20, 2017
- Accepted in final form May 24, 2018
- First Published August 1, 2018.
Author Disclosures
- Guido Zagnoli-Vieira, BSc,
- Francesco Bruni, PhD*,
- Kyle Thompson, PhD,
- Langping He, MD, PhD,
- Sarah Walker, PhD,
- Arjan P.M. de Brouwer, PhD,
- Robert Taylor, PhD, FRCPath,
- Dmitriy Niyazov, MD and
- Keith W. Caldecott, PhD
- Guido Zagnoli-Vieira, BSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Francesco Bruni, PhD*,
NONE
NONE
NONE
(1)Biomarkers Journal, Editorial board member, 2017-2018 (no compensation) (2)Brain and Nervous System Current Research, Editorial board member, 2017-2018 (no compensation)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1)ANVUR, FFABR2018, lead investigator, 2017-2018
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Kyle Thompson, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Langping He, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sarah Walker, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Arjan P.M. de Brouwer, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Robert Taylor, PhD, FRCPath,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Dmitriy Niyazov, MD and
I served on the scientific advisory board of Alexion Pharmaceuticals and Mallinckrodt ARD, Inc
NONE
I received funding for speaker travel from Sanofi/Genzyme Corporation and travel was directly booked by the company.
Molecular Syndromology editorial board 2016-18, no compensation.
NONE
NONE
NONE
I serve as a chair of adjudication committee for Stealth BioTherapeutics in Phase II clinical trial of Elamipretide in Mitochondrial Myopathy
I am a member of the Speakers' bureau of Sanofi/Genzyme Corporation
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
I served as an expert witness in 2017 for the vaccine injury in a child with mitochondrial disease
- Keith W. Caldecott, PhD
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Genome Damage and Stability Centre (G.Z-V., K.W.C.), University of Sussex, Falmer, Brighton, United Kingdom; Wellcome Centre for Mitochondrial Research (F.B., K.T., L.H., R.T.), Institute of Neuroscience, Newcastle University, Tyne, United Kingdom; Sussex Drug Discovery Centre (S.W.), University of Sussex, Falmer, Brighton, United Kingdom; Department of Human Genetics (A.P.M.d.B.), Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands; and Medical Genetics (A.P.M.d.B., D.N.), Ochsner Health Center for Children, New Orleans, LA.
- Correspondence
Dr. Caldecott k.w.caldecott{at}sussex.ac.uk
Article usage
Cited By...
Letters: Rapid online correspondence
NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.ng.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Related Articles
- No related articles found.